Standard Operating Procedure for Interim Clinical Monitoring Reports in BA/BE Studies

Department	BA-BE Studies
SOP No.	SOP/BA-BE/099/2025
Supersedes	SOP/BA-BE/099/2022
Page No.	Page 1 of 9
Issue Date	17/04/2025
Effective Date	20/04/2025
Review Date	17/04/2026

1. Purpose

To define the procedure for preparing, reviewing, and finalizing interim clinical monitoring reports during Bioavailability/Bioequivalence (BA/BE) studies. These reports ensure ongoing compliance, identify potential issues, and support timely decision-making.

2. Scope

This SOP applies to Clinical Research Associates (CRAs), Quality Assurance personnel, and the Principal Investigator (PI) involved in the monitoring and reporting of study conduct during the clinical phase of BA/BE studies.

3. Responsibilities

• Clinical Research Associate (CRA): Conducts monitoring visits, reviews data and logs, and prepares the interim monitoring report.
• PI: Ensures that observations raised in the report are resolved and all corrective actions are implemented.
• QA Officer: Reviews reports for accuracy, compliance, and completeness.
• Sponsor (if applicable): Receives interim updates and provides input on significant findings.

4. Accountability

The QA Head is accountable for ensuring that interim clinical monitoring reports are completed, reviewed, and archived in accordance with GCP, ICH, and sponsor expectations.

5. Procedure

5.1 Scheduling of Monitoring Visits

1. CRA schedules interim monitoring visits during active study phases such as dosing, sample collection, or hospitalization.
2. Provide notification to PI and Clinical Team at least 3 days in advance.

5.2 Monitoring Activities

1. Review the following on-site:
   • Informed consent forms
   • Source documents and CRFs
   • Dosing records and sample collection logs
   • AE/SAE documentation
   • Volunteer compliance and deviations
2. Verify adherence to protocol timelines and data accuracy.

5.3 Preparation of Interim Monitoring Report

1. CRA drafts the report using Annexure-1: Interim Monitoring Report Template, including:
   • Visit details
   • Study progress
   • Findings and observations
   • Deviations and pending issues
   • Corrective/Preventive Actions (CAPA)
2. Attach supporting documents such as site logs and photographs (if applicable).

5.4 Review and Distribution

1. Submit report to QA and PI for review within 3 working days post-visit.
2. Review comments are documented in Annexure-2: Monitoring Report Review Log.
3. Final report is shared with sponsor or retained in Trial Master File (TMF).

5.5 Follow-Up of Findings

1. Ensure all open issues are tracked and closed before end of study phase.
2. PI documents resolution and provides updates in Annexure-3: CAPA Implementation Log.

6. Abbreviations

• BA: Bioavailability
• BE: Bioequivalence
• CRA: Clinical Research Associate
• PI: Principal Investigator
• CRF: Case Report Form
• CAPA: Corrective and Preventive Action

7. Documents

1. Interim Monitoring Report Template – Annexure-1
2. Monitoring Report Review Log – Annexure-2
3. CAPA Implementation Log – Annexure-3

8. References

• ICH E6(R2) – Good Clinical Practice
• Indian GCP Guidelines
• Monitoring Plan and Study Protocol

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Interim Monitoring Report Template

Visit Date	Monitor	Key Findings	CAPA Suggested
15/04/2025	Ravi Nair	Deviation in dosing record	Re-training CRC

Annexure-2: Monitoring Report Review Log

Date	Reviewer	Remarks	Status
16/04/2025	Dr. Arvind Shah	Accepted with no changes	Finalized

Annexure-3: CAPA Implementation Log

Finding	CAPA	Implemented On	Verified By
Missed sample label	Label checklist introduced	17/04/2025	QA Officer

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
01/02/2022	1.0	Initial SOP	Clinical Oversight	QA Head
17/04/2025	2.0	Added annexures and structured monitoring plan	Audit Finding	QA Head